natgillin/translations-raw huggingface dataset:
The incidence of adverse reactions has been evaluated in six clinical trials involving approximately 4,000 adults and elderly receiving (Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics at least 7.5 µg HA, adjuvanted). 
Kõrvaltoimete esinemist hinnati kuue kliinilise uuringu käigus, milles osales ca 4 000 Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i (vähemalt 7,5 µg HA, adjuveeritud) saavat täiskasvanut ja eakat.
Persistence of antibodies after primary vaccination in this population was assessed by HI, SRH, and MN assays. 
Esmavaktsineerimisele järgnevat antikehade püsivust hinnati HI-, SRH- ja MN-testidega.
Muscoskeletal, connective tissue and bone disorders Very common: myalgia 
Lihas-skeleti sidekoe ja luude kahjustused Väga sage: müalgia
The European Medicines Agency has deferred the obligation to submit the results of studies with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1, A/Vietnam/1194/2004) in one or more subsets of the paediatric population in active immunisation against H5N1 subtype of Influenza A virus. 
Euroopa Ravimiamet on peatanud kohustuse esitada Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'iga (H5N1, A/Vietnam/1194/2004) läbi viidud uuringute tulemused laste ühe või mitme alarühma kohta gripiviiruse A alatüübi H5N1aktiivse immuniseerimise kohta.
As with all vaccines, Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics may not fully protect all persons who are vaccinated. 
Sarnaselt kõikidele vaktsiinidele ei pruugi Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics täielikult kaitsta kõiki vaktsineeritud isikuid.
MN results against A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from 67% (60-74) to 85% (78-90) and 65% (58-72) to 83% (77-89), respectively. 
MN tulemused A/Vietnam/1194/2004 suhtes viitavad seroprotektsiooni määrale vahemikus 67% (60-74) kuni 85% (78-90) ja serokonversiooni määrale vahemikus 65% (58-72) kuni 83% (77-89).
Vasculitis with transient renal involvement and exudative erythema multiforme. 
Immuunsüsteemi häired Vaskuliit koos mööduva neerude haaratusega ja multiformne eksudatiivne erüteem.
MN results against A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from of 57% (50-64) to 79% (68-87) and 55% (48-62) to 58% (47-69) respectively. 
MN tulemused A/Vietnam/1194/2004 suhtes viitavad seroprotektsiooni määrale vahemikus 57% (50-64) kuni 79% (68-87) ja serokonversiooni määrale vahemikus 55% (48-62) kuni 58% (47-69).
All (100%) animals receiving 2 doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics were protected, and 94% of animals receiving a single dose of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics were protected. 
Kaitstud olid kõik (100%) loomad, kellele manustati 2 annust Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i ja 94% loomadest, kellele manustati 1 annus Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i.
A single vaccination with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1, A/Vietnam/1194/2004) induced high and rapid serological response in subjects primed 6-8 years previously with two doses of a different surrogate H5N vaccine, having same formulation as Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics but using the strain H5N3. 
Ühekordne vaktsineerimine Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'iga (H5N1, A/Vietnam/1194/2004) kutsus esile kõrge ja kiire seroloogilise vastuse isikutel, keda oli 6...8 aastat varem vaktsineeritud kahe annuse teistsuguse surrogaat-H5N-vaktsiiniga, millel oli Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'iga sama formulatsioon, kuid erinev tüvi, H5N3.
QUALITATIVE AND QUANTITATIVE COMPOSITION Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain: 
Gripiviiruse pinnaantigeenid (hemaglutiniin ja neuraminidaas)* tüvest:
Generalised skin reactions including itching, urticaria (hives), rash or swelling of the skin and mucous membranes. 
Üldised nahareaktsioonid, sealhulgas sügelemine, nõgestõbi (villiline lööve), naha ja limaskestade lööve või paistetus.
Common: Brusing of the skin at the injection site, fever and nausea, generally feeling unwell and shivering. 
Sage: Verevalum süstekohas, palavik ja iiveldus, üldine halb enesetunne ja värisemine.
A/Vietnam/1194/2004 (H5N1)-like strain (NIBRG-14) 7.5 micrograms haemagglutinin Adjuvant: MF59C.1 oil composed of squalene, polysorbate 80 and sorbitan trioleate. 
A/Vietnam/1194/2004 (H5N1) sarnane tüvi (NIBRG-14) 7,5 mikrogrammi hemaglutiniini
The safety and efficacy of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics in subjects under 18 years of age have not yet been established. 
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i ohutus ja efektiivsus alla 18- aastastel lastel ei ole veel tõestatud.
Seroprotection rate (95%CI)* Seroconversion rate (95%CI)* Seroconversion factor (95%CI)** * measured by SRH assay ≥ 25 mm2 
Seroprotektsiooni määr (95% usaldusvahemik)* Serokonversiooni määr (95% usaldusvahemik)* Serokonversiooni faktor (95% usaldusvahemik)* * määratud SRH-testiga ≥ 25 mm ** SRH geomeetriliste keskmiste suhe
In a phase 2 clinical trial (Study V87P3) adult subjects aged 18-65 years primed 6-8 years previously with 2 doses of MF59-adjuvanted H5N3 vaccine /A/Duck/Singapore/97 were administered 2 booster doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics SRH results after the first dose, that mimic prepandemic priming plus single heterologous booster dose, met all CHMP criteria. 
Kliiniliste uuringute teises etapis (uuring V87P3) manustati isikutele vanuses 18...65 aastat, keda oli 6...8 aastat varem eelvaktsineeritud kahe annuse MF59-adjuveeritud H5N3 vaktsiiniga /A/Duck/Singapore/97, kaks Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i korduvannust.
Seroprotection rate (95%CI)* Seroconversion rate (95%CI)* Seroconversion factor (95%CI)** 
Seroprotektsiooni määr (95% usaldusvahemik)* Serokonversiooni määr (95% usaldusvahemik)* Serokonversiooni faktor (95% usaldusvahemik)**
Two doses of vaccine containing H5N1 (A/Vietnam/1194/2004; 7.5 µg HA/dose adjuvanted) were administered three weeks apart to 156 healthy adults. 
156 tervele täiskasvanule manustati kaks annust H5N1 (A/Vietnam/1194/2004; 7,5 µg hemaglutiniini [HA]/annuse kohta koos adjuvandiga) vaktsiini kolmenädalaste vahedega.
Potassium chloride Potassium dihydrogen phosphate Disodium phosphate dihydrate Magnesium chloride hexahydrate Calcium chloride dihydrate Sodium citrate 
naatriumkloriid kaaliumkloriid kaaliumdivesinikfosfaat dinaatriumfosfaatdihürdaat magneesiumkloriidheksahüdraat kaltsiumkloriiddihüdraat naatriumtsitraat sidrunhape süstevesi
MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION 
Bioloogilise toimeaine tootjate nimi ja aadress
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a vaccine for use in adults (from 18 to 60 years old). 
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics on vaktsiin täiskasvanutele (vanuses 18...60 aastat) ja eakatele (üle 60 aastased).
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics containing HA from A/Vietnam/1194/2004 (homologous to the challenge strain) and an Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics -like H5N1 vaccine, containing hemagglutinin from the A/turkey/Turkey/1/2005-like (heterologous to the challenge strain) were tested. 
Testiti A/Vietnam/1194/2004-st (homoloogne väljakutse tüvega) pärinevat HA-d sisaldavat Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i ja Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'ile sarnast H5N1 vaktsiini, mis sisaldab A/turkey/Turkey/1/2005sarnasest tüvest (heteroloogne väljakutse tüvele) pärinevat hemaglutiniini.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics should be used in accordance with official recommendations. 
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i tuleb kasutada vastavalt ametlikele soovitustele.
Skin and subcutaneous tissue disorders Common: sweating Uncommon: urticaria Rare: eye swelling 
Naha ja nahaaluskoe kahjustused Sage: higistamine Aeg-ajalt: nõgestõbi
Very limited data in subjects with co-morbidities, including immunocompromised subjects are available for this H5N1 vaccine. 
Käesoleva H5N1 vaktsiini kohta on äärmiselt vähe andmeid kaasuvate haigustega, sh immuunkomprimeeritud isikute osas.
The side effects listed below have occurred with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics in clinical studies in adults, including the elderly: 
Allpool loetletud kõrvaltoimed on esinenud Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i kasutamisel kliinilistes uuringutes täiskasvanute, sealhulgas eakatega:
Muscoskeletal, connective tissue and bone disorders Muscular weakness, pain in extremities. 
Lihas-skeleti sidekoe ja luude kahjustused Lihasnõrkus, valu jäsemetes.
Information from non-clinical trials 
Teave mittekliinilistest katsetest
PSURs 
PAPPKARP
It is estimated that more than 90,000 women have been vaccinated during pregnancy with H1N1v vaccine Focetria which contains the same amount of adjuvant MF59C.1 as. Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics However information on outcomes is currently limited. 
Hetkearvestuse kohaselt on raseduse ajal vaktsineeritud üle 90 000 naise H1N1v vaktsiini Focetria'ga, mis sisaldab Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'iga võrdses koguses adjuvanti MF59C.1.
History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues (egg and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB)) of this vaccine. 
Anamneesis anafülaktiline (st eluohtlik) reaktsioon vaktsiini ükskõik millise koostisaine või jääkide suhtes (muna- ja kanavalgud, ovalbumiin, kanamütsiin ja neomütsiinsulfaat, formaldehüüd ja tsetüültrimetüülammooniumbromiid (CTAB)).
Limited data was obtained from women who became pregnant during the course of clinical trials with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics or H1N1v vaccines adjuvanted with MF59C.1. 
Piiratud hulgal andmeid koguti naistelt, kes rasestusid Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics´i või MF59C.1ga adjuveeritud H1N1v vaktsiinidega läbi viidud kliiniliste uuringute käigus.
Up to 50% of the elderly subjects immunised with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics were seroprotected at six months. 
Kuni 50% eakatest Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'iga vaktsineeritud uuringus osalejatest saavutas kuuendal kuul seroprotektsiooni.
Do not use Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics after the expiry date which is stated on the carton and the label. 
Ärge kasutage Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i pärast kõlblikkusaega, mis on märgitud karbil ja sildil.
Disorders of the gut such as nausea, vomiting, abdominal pain and diarrhoea. 
Seedetrakti häired, nagu iiveldus, oksendamine, kõhuvalu ja diarröa.
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH 
BIOLOOGILISE TOIMEAINE TOOTJAD JA TOOTMISLOA HOIDJA, KES VASTUTAB RAVIMIPARTII KASUTAMISEKS VABASTAMISE EEST
A third (booster) dose of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics was administered 6 months onwards after the primary vaccination. 
Kolmas (korduv) Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i annus manustati kuus kuud pärast esmast vaktsineerimist.
Palpitation, tachycardia. 
Südame häired Palpitatsioon, tahhükardia.
Therefore the data indicate that Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics may be co-administered with non-adjuvanted seasonal influenza vaccines (with injections made into opposite limbs). 
Seega võib nende andmete põhjal järeldada, et Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i võib manustada koos adjuveerimata sesoonse gripiviiruse vaktsiinidega (süsted tuleb teha erinevatesse jäsemetesse).
Data obtained in adults showed that Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics can be given at the same time as nonadjuvanted seasonal influenza vaccines, with injections made into separate limbs. 
Täiskasvanutelt saadud andmed on näidanud, et Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i võib manustada samal ajal mitteadjuveeritud sesoonse gripiviiruse vaktsiiniga, tingimusel, et vaktsiinid süstitakse erinevatesse jäsemetesse.
Toddlers (6-<36 months) Children (3-<9 years) Adolescents (9-<18 years) N=91 
Noorukid (9...<18 years)
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in the adults measured by SRH assay was as follows: 
Seroprotektsiooni määr*, serokonversiooni määr* ja serokonversiooni faktor** anti-HA-antikehade suhtes H5N1 A/Vietnam/1194/2004-le täiskasvanutel, määratuna SRH-testide põhjal, olid järgmised:
No increase in reactions was reported when a booster dose is administered 6 months-18 months later after the initial dosing series. 
Juhul kui korduvannus manustatakse vähemalt 6 kuud kuni 18 kuud pärast esialgsete annuste seeriat, reaktsioonide arv ei suurene.
Two doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics were administered three weeks apart and a third dose 12 months following the first dose. 
Kolmenädalaste vahedega manustati kaks annust Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i ning 12 kuud pärast esimest annust manustati kolmas annus.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics suspension for injection in pre-filled syringe Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) 
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics süstesuspensioon eeltäidetud süstlas Pre-andeemiline gripiviiruse vaktsiin (H5N1) (pinnaantigeen, inaktiveeritud, adjuveeritud)
Study V87P1 21 days after 2 
Uuring V87P1 21 päeva pärast 2. annust
very rare (affects less than 1 user in 10,000) 
aeg-ajalt (tekib 1 kuni 10 kasutajal 1 000-st) harv (tekib 1 kuni 10 kasutajal 10 000-st) väga harv (tekib vähem kui 1 kasutajal 10 000-st)
Limited data was obtained from women who became pregnant with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics during the course of clinical trials. 
Piiratud hulgal andmeid koguti naistelt, kes rasestusid Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'iga läbi viidud kliiniliste katsete jooksul.
Rare: Convulsions, eye swelling and anaphylaxis. 
Harv: Krambid, silmade paistetus ja anafülaksia.
SRH Seroprotection 
Baasserostaatus
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 0.5 ml 
PAKENDI SISU KAALU, MAHU VÕI ÜHIKUTE JÄRGI
What Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics looks like and contents of the pack Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a suspension for injection in a pre-filled syringe. 
Kuidas Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics välja näeb ja pakendi sisu Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics on süstesuspensioon eeltäidetud süstlas.
In a clinical trial evaluating 4 different vaccination schedules in 240 subjects 18 to 60 years of age, where the second dose was after either 1, 2, 3 or 6 weeks after the first Prepandemic Influenza vaccine 
Kliinilistes katsetes, kus hinnati nelja erinevat vaktsineerimisgraafikut 240 osalejal vanuses 18...60 aastat, ja kus teine annus manustati kas 1, 2, 3 või 6 nädalat pärast esimest Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i annust, saavutati SRH Inimravimite komitee kriteeriumid kõigis vaktsiinigraafiku gruppides kolm nädalat pärast 2. vaktsineerimist.
In the event of an officially declared influenza pandemic due to A/H5N1 virus, persons previously vaccinated with one or two doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics that contained HA antigen derived from a different clade of the same influenza subtype as the influenza pandemic strain may receive a single dose of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics instead of two doses that are required in previously unvaccinated individuals (see section 5.1). 
Ametlikult väljakuulutatud A/H5N1 viiruse poolt põhjustatud gripipandeemia korral piisab isikutel, keda on eelnevalt vaktsineeritud ühe või kahe annuse Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'iga, mis sisaldas gripi pandeemilise tüvena sama gripi alatüübi erinevast grupist tuletatud HA antigeeni, ühest Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i annusest.
nd dose 1 
1. süst
Across all ages, low percentages of subjects reported fever. 
Palavikku esines kõigi vanusegruppide lõikes harva.
The following additional adverse events were reported from post-marketing surveillance with seasonal non-adjuvanted trivalent vaccines in all age groups and an MF59 seasonal adjuvanted trivalent vaccine with a composition similar to Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (surface antigen, inactivated, adjuvanted with MF59C.1) that is licensed for use in elderly subjects 65 years of age and older: Blood and lymphatic system disorders 
Kõikides vanusegruppides kasutatavate sesoonsete adjuveerimata trivalentsete vaktsiinide ja Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics' iga sarnase koostisega (pinnaantigeen, inaktiveeritud, adjuveeritud MF59C.1-ga) sesoonsete trivalentsete adjuveeritud MF59 vaktsiinide, mis on litsentseeritud kasutamiseks eakatel, üle 65 aasta vanustel isikutel, turustamisjärgse jälgimise põhjal on teatatud lisaks järgnevate kõrvaltoimete esinemisest.
PHARMACEUTICAL FORM Suspension for injection in pre-filled syringe. 
Süstesuspensioon eeltäidetud süstlas.
These side effects may occur with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics. 
Neid kõrvaltoimeid võib esineda ka Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i kasutamisel.
Side effects from clinical study in children (6 months to 17 years of age) 
Kõrvaltoimed kliinilistest uuringutest lastega (vanuses 6 kuud kuni 17 aastat) Sama vaktsiiniga teostati kliiniline uuring lastel.
You should not receive Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics: 
Te ei tohi saada Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i:
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted). 
Pre-pandeemiline gripiviiruse vaktsiin (H5N1) (pinnaantigeen, inaktiveeritud, adjuveeritud).
There are no data on co-administration of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics with other vaccines. 
Puuduvad andmed Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i koosmanustamise kohta teiste vaktsiinidega.
After 3 weeks from the 2 
43. päevast 1. päevani
The magnitude of immune response was lower in the group who received the 2 
Immuunvastus oli madalam grupis, kus 2. annus manustati 1 nädal hiljem, ja kõrgem pikemate intervalllidega grupis.
No post-marketing surveillance data are available following Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics administration. 
Puuduvad turustamisjärgse jälgimise andmed pärast Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i manustamist.
Important information about some of the ingredients of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics 
Oluline teave mõningate Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i koostisainete suhtes
Your doctor needs to assess the benefits and potential risks of giving you the vaccine if you are pregnant or breast-feeding. 
Kui te olete rase või toidate rinnaga, peab teie arst kaaluma vaktsiini manustamise võimalikku kasu ja potentsiaalseid riske.
This section describes the clinical experience with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics following a two-dose administration and booster. 
Käesolev lõik kirjeldab kahe annuse Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i ja korduvvaktsiini manustamise järgset kliinilist kogemust.
PSUR submission when Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is used during an influenza pandemic: 
Perioodiliste ohutusalaste uuenduste raportite esitamine Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i kasutamisel gripipandeemia ajal: